North Bergen, New Jersey--(Newsfile Corp. - July 30, 2024) - Apollo Biowellness, Inc. (OTC Pink: KOAN) the "Company") is pleased…
Nascent CEO-Sean Carrick-Discusses Phase I Results and Forward Clinical Strategy while laying out Investment Opportunity of the Company NORTH PALM…
Strategic in-license from Cortice Bioscience is highly synergistic with the ongoing potentially pivotal Berubicin program and demonstrates further commitment to…
Preclinical data showed strong antibody responses with no measurable pro-inflammatory T cell responses against AßO and support novel approach for…
SNK01, a cryopreserved autologous non-genetically modified NK cell product, is able to effectively reduce α-synuclein (α-syn) protein levels in the…
Studied across thousands of patients and supported by hundreds of clinical publications, the TCAR pioneer has continually delivered positive outcomes…
BOSTON, July 30, 2024 (GLOBE NEWSWIRE) -- CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for…
NEW YORK, July 30, 2024 (GLOBE NEWSWIRE) -- Ovid Therapeutics Inc. (NASDAQ: OVID), a biopharmaceutical company dedicated to meaningfully improving…
Study to explore role of the Company’s anti-NRP2 antibodies in glioblastoma multiforme (GBM), the most common type of primary brain…
The collaboration aims to identify and develop accessible, minimally invasive blood-based biomarkers specific for tau pathology in the brainThese tools…